PREVALENCE OF BRCA1 AND BRCA2 MUTATIONS IN WOMEN WITH EARLY-ONSET BREAST CANCER
DOI:
https://doi.org/10.71000/d1xdm317Keywords:
BRCA1, , BRCA2, Breast Neoplasms, Early Diagnosis, Genetic Testing, Pakistan, PrevalenceAbstract
Background: Early-onset breast cancer poses significant clinical challenges due to its aggressive behavior and genetic predisposition. Mutations in the BRCA1 and BRCA2 genes are strongly linked to hereditary breast cancer, especially in younger patients. However, regional data on their prevalence remains limited in South Asian populations, particularly in Pakistan.
Objective: To determine the prevalence of BRCA1 and BRCA2 gene mutations among women diagnosed with early-onset breast cancer in the Lahore region of Pakistan.
Methods: A cross-sectional study was conducted over eight months involving 200 women aged ≤39 years with histologically confirmed breast cancer. Participants were recruited from three major oncology centers in Lahore. Clinical and demographic data were collected through structured interviews. Peripheral blood samples were analyzed using next-generation sequencing (NGS) for BRCA1/2 mutations. Statistical analysis was performed using SPSS v26, with significance set at p<0.05.
Results: BRCA1 mutations were identified in 24 patients (12%) and BRCA2 mutations in 18 (9%). Variants of uncertain significance were found in 6 patients (3%), while 152 (76%) tested negative for both mutations. Mutation prevalence was significantly higher in patients with a family history of breast or ovarian cancer and among those with triple-negative breast cancer. BRCA1 mutations were most common in triple-negative cases (25%), while BRCA2 mutations showed a slightly more even distribution across subtypes.
Conclusion: A considerable proportion of early-onset breast cancer patients in Pakistan carry BRCA mutations. These findings underscore the importance of routine genetic screening and tailored risk management strategies in young breast cancer patients, irrespective of family history.
References
Li J, He P, Cai Q, Chen L, Wang Y, Cai W, et al. Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China. J Cancer Res Clin Oncol. 2024;150(6):322.
Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, et al. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol. 2021;39(31):3430-40.
Abdel-Razeq H, Abujamous L, Abunasser M, Edaily S, Bater R. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan. Sci Rep. 2021;11(1):14906.
Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, et al. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Sci Rep. 2021;11(1):14747.
Kotsopoulos J, Maxwell CA, Lubinski J, Huzarski T, Kim RH, Tung N, et al. Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant. Br J Cancer. 2025;133(1):104-10.
Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. J Natl Cancer Inst. 2022;114(4):540-52.
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155-64.
Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, et al. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families. Genes (Basel). 2021;12(7).
Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, et al. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. Ann Oncol. 2024;35(9):792-804.
Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers? Ann Surg Oncol. 2021;28(10):5657-62.
Schwartz M, Ibadioune S, Delhomelle H, Barraud S, Caputo SM, Trabelsi-Grati O, et al. High prevalence of constitutional BRCA1 epimutation in patients with early-onset triple-negative breast cancer. Clin Epigenetics. 2025;17(1):91.
Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, et al. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas. J Cancer Res Clin Oncol. 2021;147(10):2935-44.
Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, et al. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Commun Biol. 2020;3(1):578.
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022;126(2):302-9.
Tüchler A, De Pauw A, Ernst C, Anota A, Lakeman IMM, Dick J, et al. Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction. Breast. 2024;73:103615.
Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, et al. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. J Clin Oncol. 2025;43(14):1706-19.
Li S, Madanat-Harjuoja L, Leslie G, Barnes DR, Bolla MK, Dennis J, et al. Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers. J Natl Cancer Inst. 2025;117(4):728-36.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, et al. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer. 2024;130(16):2746-62.
Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, et al. Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. Cancer Prev Res (Phila). 2021;14(1):131-44.
Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS. BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015. Med Care. 2020;58(11):963-7.
Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, et al. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. Int J Cancer. 2020;147(5):1334-42.
Abu-Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, et al. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Sci Rep. 2020;10(1):17573.
Dias Nunes J, Demeestere I, Devos M. BRCA Mutations and Fertility Preservation. Int J Mol Sci. 2023;25(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Irfan Ishaque, Syed Gufran Sadiq Zaidi, Amna Noor, Tahir Hafeez, Ariba Shah, Roha Tariq, Shagufta Rasool, Syeda Neha Zainab (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
